Immunodiagnostic Systems Holdings plc provided trading update for the year 2016. Total revenues are expected to be £39 million (2015: £45 million), in line with the guidance given in November 2015. The decrease in revenues year on year is mainly due to further reductions in manual assay business, where test volumes continue to migrate to automated solutions offered by the company and others.

In addition, the company continuing to lose automated 25-OH Vitamin D business as the larger laboratories migrate test volumes previously run on the iSYS analyzer to workhorses (that is high-throughput analyzers) when their contracts with IDS come due for renewal. These revenue trends are expected to continue into the current financial year.